Hangzhou Sinopep Pharmaceutical Inc

Sinopep-Allsino Biopharmaceutical Co Ltd.is a biomedical enterprise with the main business of research and development, production, sales and technical services of peptides and small molecule drugs. The company is a national high-tech enterprise and provincial science and technology enterprise, established in April 2009, located in the national Lianyungang Economic and Technological Development Zone. The company was listed on the New Third Board in January 2016 (Stock Abbreviation: Sinopep Biology, Code: 835572).There are more than 800 employees. Through technological innovation, the company is committed to breaking through the technical bottleneck of drug research and development and production, building a whole industry chain from pharmaceutical intermediates, APIs to formulation, and providing green, low-cost, high-quality and efficient pharmaceutical-related products and technical services for the global market. In terms of R & D, the company insists on technological innovation as the driving force, constantly strengthens the construction of independent innovation capability, and invests more than 10% of R & D expenses in sales every year for many years. The company has three provincial-level R & D centers, namely, Sinopep Biology, Allsino and Simbospharm.A research and development team with international technical level led by experts of national key talent introduction project and provincial talent plan has been set up, with more than 160 people, including more than 40 master's and doctor's degrees and 6 returnees. The R & D center provides solid technical support for the business layout of the company's whole industry chain by integrating software and hardware conditions and realizing technology integration.In addition, the company has cooperated with Professor Hartmut Michel, a German biochemist and Nobel Prize winner in chemistry, to set up a Nobel Prize workstation to accelerate the company's technological innovation. The company has more than 50 authorized patents, more than 50 patents in the application, and has established good cooperation with many universities and scientific research institutes. In terms of production, Sinopep has established two modern production bases in Lianyungang, Jiangsu Province and Jiande, Zhejiang Province, which cover two major fields of peptide and small molecule chemical drugs, meet international regulations and market standards, and cover the large-scale production capacity of the whole industry chain of advanced pharmaceutical intermediates-raw materials-formulation.The company's hard capsules, tablets, freeze-dried powder injection, small volume injections and some APIs have passed the national GMP certification, and the quality system of peptide APIs has passed the cGMP on-site inspection of the US FDA three times in 2014, 2016 and 2019. In the re-inspection in January 2019, the company passed the zero defect ( NAI) successfully, which laid the foundation for the company's products to enhance the competitiveness of the international market. In terms of market, Sinopep adheres to the internationalization strategy, through the internationalization of varieties and business layout, talent team and production system construction, so that the company's products and technology have international competitiveness. After years of development, the company has won the recognition of many world-renowned pharmaceutical enterprises by virtue of advanced R & D technology and high standard quality management system, and has established a long-term and stable cooperative relationship. In the future, Sinopep will drive its development by innovation, continue to increase technological innovation, and eventually grow into an internationally renowned biopharmaceutical enterprise with peptide innovative drugs as the main body, blockbuster generic drugs and technical services as the two wings, with R & D and production capacity of the whole pharmaceutical industry chain.